MaxCyte
MXCT
98 hedge funds and large institutions have $502M invested in MaxCyte in 2022 Q1 according to their latest regulatory filings, with 17 funds opening new positions, 36 increasing their positions, 34 reducing their positions, and 22 closing their positions.
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
6% more repeat investments, than reductions
Existing positions increased: 36 | Existing positions reduced: 34
0.68% more ownership
Funds ownership: 66.79% → 67.47% (+0.68%)
5% less funds holding
Funds holding: 103 → 98 (-5)
23% less first-time investments, than exits
New positions opened: 17 | Existing positions closed: 22
27% less capital invested
Capital invested by funds: $687M → $502M (-$185M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
American Century Companies
Kansas City,
Missouri
|
+$11.3M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$10.1M |
| 3 |
Millennium Management
New York
|
+$9.61M |
| 4 |
VP
Vitruvian Partners
London,
United Kingdom
|
+$7.21M |
| 5 |
Goldman Sachs
New York
|
+$5.21M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NTCM
Nine Ten Capital Management
Chicago,
Illinois
|
-$19M |
| 2 |
Artisan Partners
Milwaukee,
Wisconsin
|
-$11.2M |
| 3 |
Marshall Wace
London,
United Kingdom
|
-$10.1M |
| 4 |
QP
Quilter Plc
London,
United Kingdom
|
-$4.49M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$3.55M |
MXCT Hedge Fund Activity: Q1 2022 in Review
98 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in MaxCyte (MXCT) for Q1 2022, worth a combined $502M — down 27% from $687M a quarter earlier.
Sellers outnumbered buyers: 22 funds closed out of MXCT and 17 opened new positions — a net loss of 5 holders — while 34 trimmed existing stakes and 36 added.
The largest buyer was American Century Companies, opening a new position worth an estimated $11.3M. The largest seller was Nine Ten Capital Management, exiting entirely with an estimated $19M sold.
- 98 institutional investors held MaxCyte (MXCT) as of Q1 2022, down from 103 in Q4 2021.
- Funds reported $502M of MaxCyte stock for Q1 2022, down 27% quarter-over-quarter.
- 17 funds opened new MaxCyte positions in Q1 2022 and 22 closed out, a net change of -5 holders.
- The largest MaxCyte buyer in Q1 2022 was American Century Companies, an estimated $11.3M added.
- The largest MaxCyte seller in Q1 2022 was Nine Ten Capital Management, an estimated $19M sold.
Based on aggregated 13F filings for Q1 2022.